ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P 500
5,745.37
0.40%
US Tech 100
19,587.60
0.80%
Dow Jones
42,175.11
0.62%
Brent Oil
70.855
-3.19%
Bitcoin
64,715.06
2.51%
Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. NeuroSense Therapeutics Ltd (NRSN)

  7. NeuroSense Therapeutics Ltd (NRSN) News

NRSN

NeuroSense Therapeutics (NRSN)

NeuroSense Therapeutics Ltd
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:NRSN
DateTimeSourceHeadlineSymbolCompany
09/24/20249:05AMPR Newswire (US)NeuroSense Therapeutics Granted Key U.S. Patent for Novel PrimeC Formulation, its Lead Asset for ALS and Alzheimer'sNASDAQ:NRSNNeuroSense Therapeutics Ltd
09/24/20249:00AMPR Newswire (US)NeuroSense Regains Compliance with NASDAQ Minimum Bid Price RuleNASDAQ:NRSNNeuroSense Therapeutics Ltd
08/30/20245:00PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:NRSNNeuroSense Therapeutics Ltd
08/30/20244:30PMPR Newswire (US)NeuroSense Therapeutics Announces Receipt of Nasdaq Minimum Bid Price NotificationNASDAQ:NRSNNeuroSense Therapeutics Ltd
08/28/20247:05AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:NRSNNeuroSense Therapeutics Ltd
08/26/20248:00AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:NRSNNeuroSense Therapeutics Ltd
08/16/20244:06PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:NRSNNeuroSense Therapeutics Ltd
08/16/20244:05PMEdgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:NRSNNeuroSense Therapeutics Ltd
08/07/20242:00PMPR Newswire (US)NeuroSense Therapeutics Announces Private Placement with Senior Management Participation at Premium to Market PriceNASDAQ:NRSNNeuroSense Therapeutics Ltd
08/07/20249:00AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:NRSNNeuroSense Therapeutics Ltd
08/01/20249:24AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:NRSNNeuroSense Therapeutics Ltd
08/01/20249:15AMPR Newswire (US)NeuroSense Therapeutics Announces Positive Biomarker Data from ALS Phase 2b Clinical TrialNASDAQ:NRSNNeuroSense Therapeutics Ltd
07/09/20249:27AMPR Newswire (US)NeuroSense's PARADIGM ALS Clinical Trial Demonstrates Up to 73% Improved Complication-Free Survival Following Statistically Significant Slowing of Disease ProgressionNASDAQ:NRSNNeuroSense Therapeutics Ltd
07/01/20248:00AMPR Newswire (US)NeuroSense Demonstrates Statistically Significant Efficacy and Survival Benefits in People Living with ALS: The Promising Results from the 12-Month PARADIGM Study Highlight PrimeC's Potential as a Disease Modifying DrugNASDAQ:NRSNNeuroSense Therapeutics Ltd
06/24/20249:00AMPR Newswire (US)NeuroSense Management Provides Corporate Update and First Quarter 2024 Financial ResultsNASDAQ:NRSNNeuroSense Therapeutics Ltd
06/21/20244:30PMPR Newswire (US)NeuroSense Receives Delisting Notice from Nasdaq and Intends to AppealNASDAQ:NRSNNeuroSense Therapeutics Ltd
05/20/20249:00AMPR Newswire (US)NeuroSense Vice President of R&D Shiran Zimri, Ph.D. to Participate in the 3rd Annual ALS Drug Development SummitNASDAQ:NRSNNeuroSense Therapeutics Ltd
05/14/20249:05AMPR Newswire (US)NeuroSense Partners with PhaseV to Optimize Upcoming ALS Phase 3 Trial Using Advanced Causal Machine LearningNASDAQ:NRSNNeuroSense Therapeutics Ltd
05/07/20248:45AMPR Newswire (US)NeuroSense Announces New Positive Data Analysis from PARADIGM Clinical Trial Demonstrating Statistically Significant Slowing of Disease Progression in High-Risk ALS PatientsNASDAQ:NRSNNeuroSense Therapeutics Ltd
05/02/20249:19AMPR Newswire (US)NeuroSense Announces First Quarter 2024 Business UpdateNASDAQ:NRSNNeuroSense Therapeutics Ltd
04/22/20248:30AMPR Newswire (US)NeuroSense and Genetika+ Initiate Precision Medicine Collaboration Beginning with Ongoing Phase 2 Clinical Trial in Alzheimer's DiseaseNASDAQ:NRSNNeuroSense Therapeutics Ltd
04/18/20248:30AMPR Newswire (US)NeuroSense Presents Positive Data Validating Phase 2b Topline Readout During Emerging Science Presentation at the American Academy of Neurology Annual MeetingNASDAQ:NRSNNeuroSense Therapeutics Ltd
04/12/20248:30AMPR Newswire (US)NeuroSense to Present PARADIGM Data at the American Academy of Neurology Annual Meeting April 16, 2024NASDAQ:NRSNNeuroSense Therapeutics Ltd
04/10/20247:16PMPR Newswire (US)NeuroSense Announces Pricing of $4.5 Million Registered Direct Offering and Concurrent Private PlacementNASDAQ:NRSNNeuroSense Therapeutics Ltd
04/09/20248:30AMPR Newswire (US)NeuroSense Collaborates with Lonza to Identify Exosome-based Biomarkers, in order to Advance Neurodegenerative Disease Treatments and DiagnosticsNASDAQ:NRSNNeuroSense Therapeutics Ltd
04/05/20249:29AMPR Newswire (US)NeuroSense Announces Year End 2023 Financial Results and Provides Business UpdateNASDAQ:NRSNNeuroSense Therapeutics Ltd
02/22/20248:25AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:NRSNNeuroSense Therapeutics Ltd
02/22/20248:25AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:NRSNNeuroSense Therapeutics Ltd
02/21/20248:30AMPR Newswire (US)NeuroSense Reports Additional Positive Results from its ALS Phase 2b PARADIGM TrialNASDAQ:NRSNNeuroSense Therapeutics Ltd
02/13/20241:20PMEdgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:NRSNNeuroSense Therapeutics Ltd
 Showing the most relevant articles for your search:NASDAQ:NRSN

Your Recent History

USOTC
TPTW
TPT Global Tech (CE)
USOTC
AXXA
Exxe (PK)
USOTC
SHMP
NaturalShrimp (QB)
USOTC
IDVV
International Endeavors (PK)
NASDAQ
RNAZ
TransCode Therapeutics
USOTC
NBRI
North Bay Resources (PK)
USOTC
AHRO
Authentic (PK)
USOTC
ENZC
Enzolytics (PK)
USOTC
QSEP
QS Energy (PK)
COIN
BTCUSD
Bitcoin
NYSE
AMC
AMC Entertainment
NASDAQ
TSLA
Tesla
NASDAQ
NVDA
NVIDIA
USOTC
TGRP
TRON (PK)
USOTC
HCMC
Healthier Choices Manage... (PK)
USOTC
HIRU
Hiru (PK)
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

United States
Company
Business
Popular
Get The App
App Store
Google Play

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved